Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vilazodone: Phase III data

In a double-blind, U.S. Phase III trial (GNSC-04-DP-02) in 410 patients with major depressive disorder,

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE